Latest Asx Listings News

Yowie Group Limited has extended and increased its secured working capital loan facility with Keybridge Capital, adjusting terms to support ongoing liquidity.

PARKD Limited has completed the first tranche of its $0.78 million placement, issuing over 20 million shares at 3 cents each, while launching a Share Purchase Plan for existing shareholders.

Baumart Holdings has recorded a nearly $1 million impairment on its mining equipment due to halted diamond mining operations and no clear plans for asset redeployment.

Lord Resources has completed a $814,000 placement by issuing 22 million shares, reinforcing its funding position as it advances exploration at the Ilgarari Copper Project in Western Australia.

Myer Holdings has clarified that its FY2025 earnings aligned with market forecasts, addressing concerns following a sharp share price drop after its results announcement.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Peak Rare Earths has officially been acquired by Shenghe Resources, with shareholders paid $0.443 per share and delisting from the ASX imminent. This marks a significant consolidation in the rare earths sector.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Tungsten Mining NL has successfully raised $9.5 million through a share placement to advance its Mt Mulgine gold-tungsten project, reinforcing its position in the global tungsten market.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.